GUTS Fractyl Health, Inc.
Fractyl Health, Inc. (GUTS) is expected to report earnings on November 9, 2026, after the market close. The consensus earnings estimate is a loss of $0.13 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +6.3% since its last earnings release on August 10, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Fractyl Health, Inc.
Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century.
Sector
Healthcare
Industry
Drug Manufacturers/Other